IL17A and metabolic disease: Specifically, ASFEE can significantly improve kidney function indicators and kidney pathological damage, reverse metabolic disorders caused by DDP, and exert protective effects through multiple pathways such as inhibiting NF-κB p65 activation, regulating the PI3K/Akt pathway to balance Bcl-2/Bax expression, and blocking IL-17 signal transduction.